ClinicalTrials.gg
RecruitingNCT02696265CIPAUpdated Jul 13, 2022

CFAE/Spatiotemporal Dispersion Guided Ablation Versus PVI Guided Ablation in Persistent AF

An interventional study of CFAE guided ablation and PVI guided ablation in Chronic Atrial Fibrillation, sponsored by Diagram B.V.. Recruiting at 4 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-13.

Sponsored by Diagram B.V. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Oct 2016; still recruiting 10 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 317 studies in Atrial Fibrillation with a site in France — 63 open to participants now, 87 under way, 5 of them phase 3. Atrial Fibrillation · France.

Planned enrollment
113th of 193
180 · median 250
Started
2016
with 8 others
No phase
117 of 317
32 open now
Primary completion
2025-07
later than 12 of 86 live
Registered
106th of 317
by date

Among the 317 studies in Atrial Fibrillation with a site in France, this one is the 113th largest by planned enrollment of the 193 interventional ones that give a count, is one of 9 that started in 2016, is one of 117 with no phase, reaches primary completion later than 12 of the 86 other live ones, and was the 106th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

63 of the 317 studies in Atrial Fibrillation with a site in France are open now. Recruiting first, the newest first:

58 more — sign in →

All 63 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 317 studies in Atrial Fibrillation with a site in France, or all of them as a file.
02

Study summary

Objective: The purpose of this study is to compare the efficacy and safety of ablation of Atrial Fibrillation (AF) drivers marked by spatiotemporal dispersions and Complex Fractionated Atrial Electrocardiograms (CFAEs) to Pulmonary Vein Isolation (PVI) based ablation in patients with persistent AF.

Hypothesis: CFAE/spatiotemporal dispersion guided ablation will increase AF free survival compared to a PVI guided ablation.

Patient population: Patients with persistent AF will be randomized based on a 2:1 ratio into one of two study arms:

  • CFAE/spatiotemporal dispersion guided ablation: CFAE mapping and ablation during AF aimed at restoring sinus rhythm during ablation.
  • PVI guided ablation: wide antral pulmonary vein isolation during mapping catheter control of pulmonary vein signals
Read the detailed description

Design: A prospective, multicenter, randomized unblinded clinical study.

Objective: The purpose of this study is to compare the efficacy and safety of ablation of AF drivers marked by spatiotemporal dispersions and CFAEs guided ablation to PVI guided ablation in patients with persistent AF.

Hypothesis: CFAE/spatiotemporal dispersion guided ablation will increase AF free survival compared to a PVI guided ablation.

Enrollment: 180 patients will be enrolled in this study.

Clinical Sites: International (including non EU-countries), multicenter study.

Patient population: Patients with persistent AF (defined as atrial fibrillation which is sustained beyond 7 days but no more than one year, or lasting less than 7 days but necessitating pharmacologic or electrical cardioversion, but lasting longer than 48 hours) should be documented either on 12-lead ECG, transtelephonic monitoring (TTM), ambulatory holter monitoring (HM) or telemetry strip and a physician's note showing continuous AF. Furthermore patients who have failed at least one Anti Arrhythmic Drug (AAD) (Class I or III) as evidenced by recurrent symptomatic AF or intolerable side effects of the AAD. Eligible patients who sign the study informed consent form will be randomized based on a 2:1 ratio into one of two study arms:

  • CFAE/spatiotemporal guided ablation: CFAE/spatiotemporal dispersion mapping and ablation during AF aimed at restoring sinus rhythm during ablation. Pulmonal vein isolation will be checked before and after ablation using a mapping catheter
  • PVI guided ablation: wide antral pulmonary vein isolation during mapping catheter control of pulmonary vein signals

Primary Endpoint: Freedom from recorded AF or atrial flutter or atrial tachycardia recurrences (>30 seconds) without the use of AADs through 18 months follow-up, post-blanking, on either a 12 lead ECG on visits or on 24 hour holter monitoring or on symptom driven event monitoring.

CFAE/spatiotemporal dispersions procedural details: To increase the accuracy of CFAE mapping, the Pentaray mapping catheter will be used to define spatiotemporal dispersion areas of CFAEs as specific targets of ablation as described by Seitz (see also citation) as follows. Dispersion areas are defined as clusters of electrograms, either fractionated or non-fractionated, that display interelectrode time and space dispersion at a minimum of 3 adjacent bipoles such that activation spread over all the AFCL. At each bipole in a dispersion area, one or more of the following fractionated or nonfractionated electrogram morphologies can be found:

  1. continuous, low-voltage fractionated electrograms ("continuously fractionated signal");
  2. bursts of fractionated electrograms ("trains of fractionation");
  3. fast nonfractionated electrograms (AFCL \<120 ms; "rapid fires"); and
  4. slow nonfractionated electrograms (AFCL >120 ms).

Multipolar electrogram dispersion and non-dispersion regions, illustrate that fractionated electrograms are found in both dispersion and non-dispersion regions.

CFAE software can be used, but CFAE ablation is not guided by the software, but based on visual judgement. Preferably a CFAE map will be made before ablation to judge the sites of most extensive CFAE sites. Baseline mapping in both atria will be performed during AF with the PentaRay multispline catheter sequentially positioned in various regions of the RA and LA. At each location, the catheter will be maintained in a stable position for a minimum of 2.5 s. The operator will look for dispersion areas (electrograms exhibiting both time and spatial dispersion). Where dispersion are found and/or the catheter is not stable for 2.5 s, acquisitions will be repeated.

Additional risks: No additional risks are anticipated for patients enrolled in this study compared to patients undergoing ablation of symptomatic AF outside of the study, because the same catheter is used as in patients outside the study, and both methods (PVI and CFAE) are part of daily practice. Although none reported in the literature so far, CFAE ablation may cause more extensive lesions than other ablation for persistent atrial fibrillation, especially in the posterior wall. This in turn may cause pericardial effusion, myocardial rupture and atrio-esophageal fistula. All of these are potentially life threatening. However, energy settings are changed according to myocardial wall size and pressure recordings, in order to prevent these complications. Furthermore, also in the group of wide antral ablation, the posterior wall is targeted, possibly resulting in the same events. For prevention of posterior wall injury, temperature monitoring in the oesofagus may be used.

Thrombus formation is a complication that can occur with any ablation technique. Thrombi may dislodge and embolize, causing a stroke, myocardial infarction or other ischemic event. Therefore, it is required that activated clotting time (ACT) is kept above 300 seconds. This should be monitored every 30 minutes, and heparin should be administered depending on the outcome. The operator is responsible for maintaining an adequate ACT.

Radiation exposure during the fluoroscopic imaging of the catheters may result in an increase in the lifetime risk of developing a fatal malignancy (0.1%) or a genetic defect in offspring (0.002%).

Potential Benefit: The direct benefit for patients undergoing ablation is the potential elimination of AF episodes. It is furthermore expected that quality of life will improve and less frequent hospitalization will be needed. Whether further morbidity as cerebral vascular events are prevented is subject to discussion. The information gained from the conduct of this study may benefit patients with AF by improving future treatment modalities.

03

Conditions studied

  • Chronic Atrial Fibrillation

Browse trials for

Keywords

  • Atrial Fibrillation
  • Complex Fractionated Atrial Electrocardiograms
  • Pulmonary Vein Isolation
  • Ablation
  • CFAE/spatiotemporal dispersion guided ablation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with persistent atrial fibrillation, defined as atrial fibrillation which is:

    1. Sustained beyond 7 days but no more than one year.
    2. Or lasting less than 7 days, but longer than 48 hours and necessitating pharmacologic or electrical cardioversion.
  2. Documentation of atrial fibrillation on either a 12-lead or transtelephonic monitoring (TTM), or ambulatory holter monitoring or telemetry strip and a physician's note showing continuous AF.
  3. Failure of at least one AAD (Class I or III) as evidenced by recurrent symptomatic AF or intolerable side effects of the AAD.
  4. Signed Patient Form.
  5. Age 18 years or older.
  6. Able and willing to comply with all pre- and follow-up testing and requirements.

Exclusion criteria

Exclusion Criteria:

  1. Continuous AF > 12 months (1-Year) (Longstanding Persistent AF).
  1. Previous surgical or catheter ablation for atrial fibrillation.
  2. Any cardiac surgery within the past 2 months (60 days) (includes PCI).
  3. CABG surgery within the past 6 months (180 days).
  4. Subjects that have ever undergone valvular cardiac surgical procedure (ie, ventriculotomy, atriotomy, and valve repair or replacement and presence of a prosthetic valve).
  5. Cardioversion (the inability to restore sinus rhythm for 30 secs or longer following electrical cardioversion).

    1. If a patient does not have documented evidence of being successfully cardioverted (NSR > 30 secs), the patient must be cardioverted prior to the ablation procedure with the study catheter.
    2. Failure to cardiovert based on the above criteria is considered a screen failure.
  6. Documented LA thrombus on imaging.
  7. LA size >50 mm.
  8. \< 30%.
  9. to anticoagulation (heparin or warfarin).
  10. History of blood clotting or bleeding abnormalities.
  11. Myocardial infarction within the past 2 months (60 days).
  12. Documented thromboembolic event (including ) within the past 12 months (365 days).
  13. Rheumatic Heart Disease.
  14. Uncontrolled heart failure or function class III or IV.
  15. Awaiting cardiac transplantation or other cardiac surgery within the next 12 months (365 days).
  16. Unstable angina.
  17. Acute illness or active systemic infection or sepsis.
  18. AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause.
  19. Diagnosed atrial myxoma.
  20. Presence of implanted ICD.
  21. Significant severe pulmonary disease, (eg, restrictive pulmonary disease, constrictive or ) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms.
  22. Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study.
  23. Women who are pregnant (as evidenced by pregnancy test if pre- menopausal).
  24. Enrollment in an study evaluating another device, biologic, or drug.
  25. Presence of intramural thrombus, tumor or other abnormality that precludes vascular access, or manipulation of the catheter.
  26. Presence of a condition that precludes vascular access.
  27. or other disease processes likely to limit survival to less than 12 months.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Active comparator
    CFAE guided ablation

    CFAE/spatiotemporal dispersion guided ablation: CFAE mapping and ablation during AF aimed at restoring sinus rhythm during ablation.

    Procedure: CFAE guided ablation

  • Active comparator
    PVI guided ablation

    PVI guided ablation: wide antral pulmonary vein isolation during mapping catheter control of pulmonary vein signals.

    Procedure: PVI guided ablation

Interventions

  • ProcedureCFAE guided ablation

    CFAE/spatiotemporal dispersions mapping and ablation during AF aimed at restoring sinus rhythm during ablation. Pulmonal vein isolation will be checked before and after ablation using a mapping catheter.

  • ProcedurePVI guided ablation

    Wide antral pulmonary vein isolation during mapping catheter control of pulmonary vein signals

06

What researchers measure

Primary outcomes

  1. Freedom from recorded atrial fibrillation or atrial flutter or atrial tachycardia (>30 seconds) recurrences without the use of class I or III AADs

    Freedom from recorded atrial fibrillation or atrial flutter or atrial tachycardia recurrences (\>30 seconds) without the use of class I or III AADs through 18 months follow-up, post blanking period after ablation on either a 12 lead ECG on visits or on 24 hour holter monitoring or on symptom-driven event monitoring

    Time frame: 18 months

Secondary outcomes

  1. Freedom from recorded atrial fibrillation or atrial flutter or atrial tachycardia recurrences (>30 seconds) regardless of antiarrhythmic drugs

    Freedom from recorded atrial fibrillation or atrial flutter or atrial tachycardia recurrences (\>30 seconds) through 18 months follow-up on either a 12 lead ECG on visits or on 24 hour holter monitoring or on symptom-driven event monitoring, regardless of antiarrhythmic drugs

    Time frame: 18 months

  2. Freedom from recorded atrial fibrillation or atrial flutter recurrences (>30 seconds) regardless of antiarrhythmic drugs

    Freedom from recorded atrial fibrillation or atrial flutter recurrences (\>30 seconds) through 18 months follow-up on either a 12 lead ECG on visits or on 24 hour holter monitoring or on symptom-driven event monitoring, regardless of antiarrhythmic drugs

    Time frame: 18 months

  3. Freedom from recorded atrial fibrillation or atrial flutter or atrial tachycardia recurrences (>30 seconds), without a new AAD or a previously failed AAD at a greater than the highest ineffective historical dose

    Freedom from recorded atrial fibrillation or atrial flutter or atrial tachycardia recurrences (\>30 seconds) through 18 months follow-up on either a 12 lead ECG on visits or on 24 hour holter monitoring or on symptom-driven event monitoring, without a new AAD or a previously failed AAD at a greater than the highest ineffective historical dose

    Time frame: 18 months

  4. Freedom from recorded atrial fibrillation (>30 seconds), regardless of antiarrhythmic drugs

    Freedom from recorded atrial fibrillation (\>30 seconds) through 18 months follow-up on either a 12 lead ECG on visits or on 24 hour holter monitoring or on symptom-driven event monitoring, regardless of antiarrhythmic drugs

    Time frame: 18 months

  5. Clinical/partial success at 18 months regardless of antiarrhythmic drug use

    Clinical/partial success at 18 months regardless of antiarrhythmic drug use, defined as a 75% or greater reduction in the number of AF episodes and/or the duration of AF episodes, or the % time a patient is in AF as assessed with a device capable of measuring AF burden

    Time frame: 18 months

  6. Time to first symptomatic, recorded AF recurrence

    Time to first symptomatic, recorded AF recurrence

    Time frame: 18 months

  7. Time to first electrocardioversion

    Time to first electrocardioversion

    Time frame: 18 months

  8. Symptoms associated with atrial arrhythmias

    Symptoms associated with atrial arrhythmias. Measured by CCS-SAF scale (Canadian Cardiovascular Society Severity of Atrial Fibrillation Scale)

    Time frame: 18 months

  9. Decreased anti-arrhythmic and/or anticoagulant drug use.

    Decreased anti-arrhythmic and/or anticoagulant drug use will be recorded by checking the patients medication chart

    Time frame: 18 months

  10. Quality of life at 6 and 12 months compared to baseline

    Quality of life at 6 and 12 months compared to baseline. Measured by SF36-version 2

    Time frame: 6 months and 12 months

  11. Number of redo-procedures

    Number of redo-procedures

    Time frame: 18 months

  12. Total time of fluoroscopy

    Total time of fluoroscopy

    Time frame: 1 day

  13. Total procedure time

    Total procedure time (minutes from introduction of first catheter to withdrawal of last catheter)

    Time frame: 1 day

  14. Total ablation time

    Total ablation time

    Time frame: 1 day

  15. Clinical adverse events

    Clinical adverse events (TIA,CVA, hemorrhage, tamponade, myocardial infarction, symptomatic pulmonary vein stenosis (\> 50%), or other complications associated with AF ablation as listed in and defined by the table 6 of the 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation2)

    Time frame: 18 months

  16. The combined endpoint consisting of: Mortality and Hospitalization

    The combined endpoint consisting of: Mortality and Hospitalization

    Time frame: 18 months

07

Study locations

3 of 4 sites recruiting
08

References and documents

Publications

  • Seitz J, Bars C, Theodore G, Beurtheret S, Lellouche N, Bremondy M, Ferracci A, Faure J, Penaranda G, Yamazaki M, Avula UM, Curel L, Siame S, Berenfeld O, Pisapia A, Kalifa J. AF Ablation Guided by Spatiotemporal Electrogram Dispersion Without Pulmonary Vein Isolation: A Wholly Patient-Tailored Approach. J Am Coll Cardiol. 2017 Jan 24;69(3):303-321. doi: 10.1016/j.jacc.2016.10.065. PubMed 28104073 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2016 (actual). Primary completion is estimated for Jul 2025, 105 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 105 months is above that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2016
First posted
Mar 2, 2016
StartActual
Oct 12, 2016
Primary completionEst.
Jul 2025
CompletionEst.
Jul 2025
Last update
Jul 13, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02696265
Lead sponsor
Diagram B.V.
Collaborators
Biosense Webster, Inc., Johnson & Johnson
Responsible party
Sponsor
First posted
Mar 2, 2016
Start date
Oct 12, 2016
Primary completion
Jul 2025 (estimated)
Completion
Jul 2025 (estimated)
Last update
Jul 13, 2022

Study contacts

Gery de Jong, PhD
Contact
CIPA@diagram-zwolle.nl
++31(0)38-4262999
Ilona C. Kalter, Msc
Contact
CIPA@diagram-zwolle.nl
++31(0)38-4262999
Jaap-Jan J. Smit, MD, PhD
principal investigator · Isala

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion